carisoprodol + diclofenaco de sódio + paracetamol+ cafeína
eurofarma laboratÓrios s.a. - carisoprodol, diclofenaco de sÓdio, paracetamol, cafeÍna - relaxantes musculares
paracetamol + cafeína + carisoprodol + diclofenaco sódico
legrand pharma indÚstria farmacÊutica ltda - paracetamol, cafeÍna, carisoprodol, diclofenaco sÓdico - antinflamatorios
micafungina hikma 50 mg pó para concentrado para solução para perfusão
hikma farmacêutica (portugal), s.a. - micafungina - pó para concentrado para solução para perfusão - 50 mg - micafungina 50 mg - micafungin - genérico - duração do tratamento: longa duração
micafungina mylan 50 mg pó para concentrado para solução para perfusão
viatris limited - micafungina - pó para concentrado para solução para perfusão - 50 mg - micafungina sódica 50.86 mg - micafungin - genérico - duração do tratamento: longa duração
micafungina reig jofre 50 mg pó para concentrado para solução para perfusão
laboratorio reig jofre, s.a. - micafungina - pó para concentrado para solução para perfusão - 50 mg - micafungina sódica 50.86 mg - micafungin - genérico - duração do tratamento: longa duração
paracetamol+cafeína
sanofi medley farmacÊutica ltda. - cafeÍna, paracetamol - analgesicos nao narcoticos
paracetamol + cafeína
nova quimica farmacÊutica s/a - cafeÍna, paracetamol - analgesicos nao narcoticos
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - fibrose cística - outros produtos do sistema respiratório - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 e 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 e 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - fibrose cística - outros produtos do sistema respiratório - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
tylalgin caf
geolab indÚstria farmacÊutica s/a - paracetamol, cafeÍna - analgesicos nao narcoticos